drugset
drugset / Trial / NCT05138861

A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects

NCT05138861 ↗

Phase 1 Completed 24 enrolled Tarsus Pharmaceuticals, Inc.
NaSingle-groupOpen-labelBasic science

Summary

Pharmacokinetic Study to Evaluate the Whole Blood Pharmacokinetics of TP-03 Following Six Week Topical Ocular Administration.

Timeline

Start
2021-02-09
Primary completion
2021-09-03
Completion
2021-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject lotilaner Small molecule 0.25 % Other

Indications

No indication recorded.